The new entity integrates Metrix’s expertise in behavioral science and AI-powered learning design with Versado’s specialized background in launch sales training and behavior-based change management. By merging operations, the firms aim to provide a single, cross-border partner capable of supporting pharmaceutical clients throughout the entire product lifecycle, from initial development to commercialization.

Daniel Leonard, former CEO of the CM Group, has been appointed Executive Chairman to oversee the company’s expansion. The leadership teams at both original firms emphasized that the merger provides the necessary resources to scale operations while maintaining the specialized, high-touch strategic focus that defined their work as independent entities. NaviMed Capital, which maintains a specific investment mandate in the healthcare industry, views this platform as a strategic response to the industry’s demand for faster execution and more integrated commercial performance solutions.